US Stock Market Overview – Stocks Slip Led Down by Nasdaq; McDonald’s Misses on Top and Bottom Line

Biogen surges on Alzheimer drug announcement
David Becker


Riskier assets eased, and US yields to edge lower, as the push and pull of earnings weighed on stock prices. US stocks were led down by the Nasdaq which was the worst-performing sector. The VIX volatility index moved nearly 4% higher as the S&P 500 slipped. Sectors were mixed, led down by technology shares, energy shares bucked the trend and moved higher. Biogen surged higher as the company decided to move forward with its Alzheimer’s drug. The shares surged 27%. UK lawmakers rejected the timetable for a Brexit which might lead to a general election. Stocks sold off following the announcement.

Brexit on the Back Bench

UK Lawmakers reject a timetable for Brexit deal legislation, and this means that the UK government has lost control of the process. There might even be a general election by the end of the year. While lawmakers Tuesday endorsed Prime Minister Boris Johnson’s Brexit deal, the timeline was too quick. This provides a huge amount of uncertainty within the markets, generating volatility. The question will also be whether the EU will vote on an additional extension.

McDonald’s Misses Expectations

McDonald’s missed on the bottom line as quarterly earnings fell short of estimates. Shares tumbled 5% weighing on the broader markets. The company reported earnings per share of $2.11 versus expectations that the company would earn $2.21. Revenue came in at $5.4 billion which also missed compared to expectations that the company would produce revenues of $5.5 billion. Global same-store sales came in at 5.9% versus 5.6% expected.

Biogen Surges as Company Reverses Course

Biogen stock surged on Tuesday as the company announced that it will seek regulatory approval early next year for an Alzheimer’s disease drug that had been considered a lost cause. The about-face surprised the markets which help buoy the shares. According to reports, the company took a closer look at study data that it didn’t have when its halted efforts in March. The new data indicated the drug did work in patients who received the highest dose.

Lyft Shares Surge on Financial Guidance

Lyft shares surged nearly 7% on Tuesday as the company now expects to be profitable a year ahead of analysts’ expectations. The projection for profitability by the end of 2021 is Lyft’s first public commitment regarding its timeline on the matter.

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Latest Articles

See All

Expand Your Knowledge

See All
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.